Related Experiment Video
Updated: Aug 19, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
[Criteria for suppressive dosage of thyroxine administered in thyroid cancer]
Abstract:
The investigation was concerned with thyroxine therapy for suppression of thyrotrophin synthesis in 1,033 out of 1,544 (66.9%) patients treated for papillary thyroid cancer (hemithyroidectomy--429, thyroidectomy--1,115; 484 of the latter group received radioiodinetherapy postoperatively). Thyroxine 2-5.2 mg/body mass unit was administered for 1-10 yrs (average--4. yrs). Effective daily dose depended on extent of surgery: higher dosage was required after thyroidectomy than hemithyroidectomy, and it was significantly higher after radioiodinetherapy. Bringing thyrotrophin synthesis levels down to normal was necessary in a study based on body mass and height characteristics. Also, an inverse relationship was established between suppressive dose and age. Male patients appeared to require more thyroxine per day than women. Suppressive dosage of thyroxine with regard to age, sex and treatment modality is suggested.
Related Concept Videos
Graves Disease II: Pathophysiology
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimen: Individualization
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Dosage Regimen: Multiple Oral Dosage